atopic eczema: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
460 |
4. Check minimum number of eventsNone |
460 |
5. Include endpointsNone |
460 |
6. Filter based on genotype QC (FinnGen only) |
412 |
Control definitions (FinnGen only)
- Control exclude
- L12_DERMATITISECZEMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L20-L30
- Name in latin
- Erythrodermia universalis NAS
Similar endpoints
↥List of similar endpoints to
Exfoliative dermatitis
based on the number of shared cases.
Similar with more cases:
- Dermatitis and eczema
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3058 | 1077 | 1960 |
| Only index persons | 2575 | 944 | 1631 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.03 | 0.05 |
| Only index persons | 0.05 | 0.03 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 61.96 | 61.58 | 62.08 |
| Only index persons | 60.41 | 60.15 | 60.56 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 412 | 123 | 289 |
| Unadjusted period prevalence (%) | 0.11 | 0.04 | 0.13 |
| Median age at first event (years) | 61.53 | 54.63 | 64.46 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 417
- Matched controls
- 4170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L26
ICD-10 Finland
Exfoliative dermatitis
+∞
307.7
365
*
D07AB08
ATC
desonide; topical
41.7
307.7
263
164
E000001, ,
ATC
23.9
251.7
283
338
E000003, ,
ATC
46.9
223.7
139
44
TQW80
NOMESCO Finland
Local dermatologic skincare
79.6
197.2
107
18
D07AA02
ATC
hydrocortisone; topical
17.1
192.3
219
254
L20.0
ICD-10 Finland
Besnier prurigo
+∞
173.4
154
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
17.9
173.0
171
156
D07AC01
ATC
betamethasone; topical
19.2
169.2
346
845
E0000UV, ,
ATC
21.6
166.8
359
929
D05BB02
ATC
acitretin; oral
43.5
161.5
100
30
L30.9
ICD-10 Finland
Dermatitis, unspecified
13.6
157.6
202
270
E000002, ,
ATC
16.0
157.4
165
164
134
Kela drug reimbursment
General erythroderma
368.7
152.4
145
6
D07AB02
ATC
hydrocortisone butyrate; topical
12.7
150.8
291
643
D02AE01
ATC
carbamide; topical
19.9
147.4
128
91
D07XC01
ATC
betamethasone; topical
12.2
137.2
181
247
D07AC13
ATC
mometasone; topical
10.4
131.2
266
603
D02AX
ATC
Other emollients and protectives
38.1
130.1
83
27
L30.3
ICD-10 Finland
Infective dermatitis
51.4
129.4
76
18
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
12.1
127.8
162
208
E000006, ,
ATC
16.7
122.4
115
93
L40.0
ICD-10 Finland
Psoriasis vulgaris
21.1
119.6
97
59
D07BA04
ATC
hydrocortisone and antiseptics; topical
12.9
118.0
135
149
L04AD01
ATC
ciclosporin; systemic
44.1
115.0
70
19
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
+∞
101.3
93
*
L04AX03
ATC
methotrexate; systemic
10.2
100.1
137
190
XQ802
NOMESCO Finland
Epicutan test
48.0
97.7
58
14
D07AD01
ATC
clobetasol; topical
8.5
95.0
161
286
D09AB01
ATC
zinc bandage without supplements; topical
53.9
90.0
52
11
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
12.2
81.4
90
92
H02AB06
ATC
prednisolone; systemic
8.2
79.6
334
1370
E000007, ,
ATC
15.6
77.9
72
55
D11AH01
ATC
tacrolimus; topical
421.2
73.1
71
*
N05BB01
ATC
hydroxyzine; systemic
10.9
68.7
81
90
D05AX52
ATC
calcipotriol, combinations; topical
11.1
64.8
75
81
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
156.3
63.9
66
5
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
+∞
63.2
59
*
R06AE07
ATC
cetirizine; oral
4.9
57.6
252
984
D05AX02
ATC
calcipotriol; topical
12.2
50.5
53
49
R06AE09
ATC
levocetirizine; oral
5.8
49.1
109
241
XQ800
NOMESCO Finland
Prick test
9.9
47.3
58
67
D11AX14
ATC
[U] tacrolimus
+∞
43.5
41
*
L20
ICD-10 Finland
Atopic dermatitis
+∞
43.5
41
*
D07BC01
ATC
betamethasone and antiseptics; topical
5.6
42.4
95
210
R06AX27
ATC
desloratadine; oral
4.1
40.2
160
554
D11AH02
ATC
pimecrolimus; topical
+∞
37.0
35
*
L04AA01
ATC
[U] ciclosporin
49.0
36.7
44
10
L30.0
ICD-10 Finland
Nummular dermatitis
9.0
32.7
42
51
C84.0
ICD-10 Finland
Mycosis fungoides
111.4
29.1
31
*
395
Kela drug reimbursment
Dupilumab
+∞
28.5
27
*
D07CC01
ATC
betamethasone and antibiotics; topical
4.3
28.2
86
240
A46
ICD-10 Finland
Erysipelas
3.7
27.4
110
372
XQ848
NOMESCO Finland
Dermatological photography
9.6
27.2
33
37
L40.9
ICD-10 Finland
Psoriasis, unspecified
27.2
25.7
35
14
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
+∞
25.3
24
*
D11AH05
ATC
dupilumab; topical
265.2
24.9
25
*
L40.8
ICD-10 Finland
Other psoriasis
37.1
24.6
31
9
D07AC14
ATC
methylprednisolone aceponate; topical
6.3
24.2
43
75
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.1
23.8
129
521
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
32.2
23.1
30
10
H02AB07
ATC
prednisone; oral
3.6
22.2
88
292
L04AX01
ATC
azathioprine; systemic
6.3
21.8
38
65
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
46.0
21.7
26
6
E000004, ,
ATC
19.1
21.2
32
18
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
81.1
20.9
23
*
H02AB09
ATC
hydrocortisone; systemic
9.2
20.9
26
30
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
6.4
20.3
35
59
EBA15
NOMESCO Finland
Extraction of multiple teeth
5.6
18.8
37
71
L01BA01
ATC
methotrexate; systemic
6.1
18.3
33
58
J45.0
ICD-10 Finland
Predominantly allergic asthma
4.1
17.9
53
143
L23.0
ICD-10 Finland
Allergic contact dermatitis due to metals
+∞
17.8
17
*
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
+∞
17.8
17
*
D05AX03
ATC
calcitriol; topical
16.6
17.7
28
18
R06AX22
ATC
ebastine; oral
3.1
17.2
84
314
L30.8
ICD-10 Finland
Other specified dermatitis
14.1
17.2
29
22
D11AX15
ATC
[U] pimecrolimus
+∞
16.8
16
*
S01GX01
ATC
cromoglicic acid; ophthalmic
3.0
16.7
85
325
RS340, ,
NOMESCO Finland
176.8
16.6
17
*
S87
ICPC
Dermatitis/atopic eczema
12.9
16.6
29
24
Z2446
NOMESCO Finland
Social worker
4.1
16.4
48
128
H02AB04
ATC
methylprednisolone; systemic
3.0
16.2
83
318
J01DB01
ATC
cefalexin; oral
3.2
16.1
359
2751
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.4
16.0
62
201
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
+∞
15.7
15
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
15.5
239
1532
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
15.3
85
340
L40
ICD-10 Finland
Psoriasis
11.9
15.0
27
24
L23.3
ICD-10 Finland
Allergic contact dermatitis due to drugs in contact with skin
155.2
14.6
15
*
WXQ10
NOMESCO Finland
Psoralen - Ultraviolet A therapy with systemic sensitivisation
+∞
13.6
13
*
L20.8
ICD-10 Finland
Other atopic dermatitis
+∞
13.6
13
*
L28.1
ICD-10 Finland
Prurigo nodularis
+∞
13.6
13
*
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
+∞
13.6
13
*
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.5
13.1
104
495
J01FF01
ATC
clindamycin; systemic
2.3
13.0
133
707
J45.9
ICD-10 Finland
Asthma, unspecified
2.6
12.8
90
404
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
+∞
12.6
12
*
C84.1
ICD-10 Finland
Sézary disease
+∞
12.6
12
*
L23.2
ICD-10 Finland
Allergic contact dermatitis due to cosmetics
+∞
12.6
12
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
5.6
12.4
24
45
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
3.3
12.4
50
166
ZXD31
NOMESCO Finland
Major difficulties in performing procedure
5.6
12.0
23
43
L50.0
ICD-10 Finland
Allergic urticaria
9.7
11.6
23
25
C01CA24
ATC
epinephrine; parenteral
3.8
11.6
36
100
L27.2
ICD-10 Finland
Dermatitis due to ingested food
+∞
11.5
11
*
R06AX13
ATC
loratadine; oral
2.7
11.2
66
271
RS221, ,
NOMESCO Finland
11.6
11.2
20
18
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.6
10.8
73
320
RJ411, ,
NOMESCO Finland
28.9
10.8
14
5
D06AX01
ATC
fusidic acid; topical
2.9
10.8
55
209
L40.5
ICD-10 Finland
Arthropathic psoriasis
9.6
10.6
21
23
L29.9
ICD-10 Finland
Pruritus, unspecified
10.4
10.6
20
20
L23.8
ICD-10 Finland
Allergic contact dermatitis due to other agents
+∞
10.5
10
*
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
33.5
10.4
13
*
L23.9
ICD-10 Finland
Allergic contact dermatitis, unspecified cause
33.5
10.4
13
*
RS121, ,
NOMESCO Finland
19.4
10.3
15
8
ZX112
NOMESCO Finland
Subcutaneous
5.2
10.2
21
42
L53.9
ICD-10 Finland
Erythematous condition, unspecified
10.4
10.1
19
19
S91
ICPC
Psoriasis
17.2
9.9
15
9
J01DA09
ATC
[U] cefadroxil
2.1
9.8
116
644
L28.0
ICD-10 Finland
Lichen simplex chronicus
56.3
9.7
11
*
D11AH04
ATC
alitretinoin; oral
+∞
9.4
9
*
RJ420, ,
NOMESCO Finland
22.3
9.4
13
6
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
22.3
9.4
13
6
L08.0
ICD-10 Finland
Pyoderma
22.3
9.4
13
6
JN4BD
NOMESCO Finland
Extensive body CT
2.6
9.4
60
256
L50.9
ICD-10 Finland
Urticaria, unspecified
4.4
9.2
23
54
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
4.2
9.2
25
63
S01GX02
ATC
levocabastine; ophthalmic
4.2
9.2
25
63
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
9.1
54
222
SPAT1254
SPAT
Administration of medicine
2.3
9.0
77
374
S02
ICPC
Pruritus
4.7
8.9
21
47
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.3
8.9
72
342
WW200
NOMESCO Finland
Immunization
4.9
8.7
19
40
P15
ICPC
Chronic alcohol abuse
4.2
8.6
23
57
S21
ICPC
Skin texture symptom/complaint
2.4
8.5
67
314
C03CA01
ATC
furosemide; systemic
1.9
8.5
161
1047
6929X
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[DERMATITITIS ARTEFACTA NUD]
+∞
8.4
8
*
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
7.3
8.3
19
27
J01DA01
ATC
[U] cefalexin
1.8
8.3
254
1910
S01GX08
ATC
ketotifen; ophthalmic
4.2
8.2
22
55
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
8.1
136
846
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
3.7
8.0
25
70
C10AB05
ATC
fenofibrate; oral
6.6
7.8
19
30
D64.9
ICD-10 Finland
Anaemia, unspecified
2.3
7.5
61
290
WQ021, ,
NOMESCO Finland
+∞
7.3
7
*
L23.5
ICD-10 Finland
Allergic contact dermatitis due to other chemical products
+∞
7.3
7
*
L40.1
ICD-10 Finland
Generalized pustular psoriasis
+∞
7.3
7
*
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
7.1
159
1074
D07AB01
ATC
clobetasone; topical
4.1
7.0
19
48
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.3
6.9
58
279
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.8
6.9
134
867
L04AB04
ATC
adalimumab; parenteral
8.5
6.9
14
17
H10.5
ICD-10 Finland
Blepharoconjunctivitis
7.4
6.8
15
21
J01CF05
ATC
flucloxacillin; systemic
2.7
6.7
38
152
RS311, ,
NOMESCO Finland
22.9
6.7
9
*
RS224, ,
NOMESCO Finland
22.9
6.7
9
*
D07XB05
ATC
dexamethasone; topical
5.7
6.7
18
33
RS222, ,
NOMESCO Finland
10.3
6.6
12
12
S01AD03
ATC
aciclovir; ophthalmic
3.8
6.6
20
55
H10
ICD-10 Finland
Conjunctivitis
3.0
6.5
29
102
ZY010
NOMESCO Finland
Hospital outpatient
3.2
6.5
26
86
L04AC16
ATC
guselkumab; systemic
70.9
6.4
7
*
L01.1
ICD-10 Finland
Impetiginization of other dermatoses
70.9
6.4
7
*
D07AC03
ATC
desoximetasone; topical
6.7
6.4
15
23
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.1
6.4
66
345
J45
ICD-10 Finland
Asthma
2.5
6.4
40
169
X59
ICD-10 Finland
Exposure to unspecified factor
2.0
6.3
82
465
69282
ICD-8 Finland
Other eczema and dermatitis, E microbis
+∞
6.3
6
*
6929B
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[ECZEMA INFECTIOSUM]
+∞
6.3
6
*
1XX25, ,
NOMESCO Finland
+∞
6.3
6
*
ZX196, ,
NOMESCO Finland
+∞
6.3
6
*
RJ421, ,
NOMESCO Finland
27.1
6.2
8
*
RS211, ,
NOMESCO Finland
27.1
6.2
8
*
D07XA01
ATC
hydrocortisone; topical
27.1
6.2
8
*
L04AC05
ATC
ustekinumab; parenteral
27.1
6.2
8
*
N06AA12
ATC
doxepin; systemic
2.9
6.2
29
105
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
2.9
6.1
29
106
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.5
6.0
38
161
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
119
184
8.65
78.18
2.1
1.2
4369.00
219.66
u/ml
4.72
114
167
35
18
21.11
23.89
2.2
2.1
—
—
—
0
0
115
438
3.24
23.39
5.7
4.6
258.99
243.51
u/l
0.54
110
417
298
1932
2.90
21.69
19.2
9.7
4.49
4.23
e9/l
1.37
280
1682
98
362
3.23
20.76
5.6
3.6
—
—
—
0
0
83
299
3.22
18.18
1.9
3.0
66.98
65.87
g/l
0.79
75
272
28
19
15.70
17.39
3.0
2.1
414.29
331.85
e6/l
0.39
17
13
44
110
4.35
16.39
2.2
1.7
13.19
8.14
iu/ml
—
10
32
25
40
6.58
15.18
1.1
1.0
11.04
0.46
u/ml
1.92
19
24
27
48
5.95
14.80
1.2
1.2
11.29
1.33
u/ml
1.39
18
29
102
497
2.39
12.13
8.9
6.3
1.07
1.04
mmol/l
0.51
95
457
18
11
17.03
11.77
1.8
1.0
11.24
8.31
ug/l
1.00
18
11
115
617
2.19
10.76
4.4
3.8
0.78
0.82
mmol/l
4.25
108
587
21
40
5.48
10.70
1.3
1.3
—
—
—
0
0
219
1508
1.95
10.15
7.1
5.5
34.49
35.15
g/l
0.96
208
1423
41
139
3.16
9.76
1.6
2.4
4.23
4.17
g/l
0.17
35
124
41
139
3.16
9.76
1.6
2.4
7.27
7.36
g/l
0.12
35
124
41
139
3.16
9.76
1.6
2.4
3.89
3.64
g/l
0.84
35
124
38
128
3.17
9.15
1.7
2.5
3.09
3.12
g/l
0.04
32
113
36
119
3.22
8.93
1.8
2.7
0.64
0.79
g/l
0.08
29
101
35
116
3.20
8.65
1.6
2.5
10.27
10.65
g/l
0.29
29
101
146
918
1.91
8.53
2.7
2.1
2.81
3.04
mg/l
0.61
127
790
305
2444
1.92
7.98
6.2
4.2
14.97
12.31
mm/h
1.91
298
2268
20
33
6.31
7.94
1.1
1.1
24.72
1.21
u/ml
2.02
13
18
316
2592
1.90
7.30
13.4
8.7
90.47
79.61
u/l
0.88
308
2452
18
31
6.02
6.99
1.1
1.1
24.10
0.69
u/ml
2.35
12
14
27
88
3.21
6.87
1.2
1.7
—
—
—
0
0
130
855
1.76
6.24
2.9
2.8
6.39
4.94
e6/l
0.23
119
777
112
709
1.79
6.11
1.4
1.2
4.51
1.33
u/ml
0.81
31
197
162
1146
1.68
5.90
4.3
3.6
2.34
2.34
mmol/l
0.13
144
1029
132
887
1.71
5.80
3.7
3.1
383.32
361.41
umol/l
1.37
116
782
17
46
3.81
5.70
1.2
1.2
—
—
—
0
0
146
1013
1.68
5.68
2.0
1.7
18.94
19.58
nmol/l
0.16
131
841
39
175
2.36
5.45
1.6
2.2
1.60
1.43
g/l
0.48
31
159
31
125
2.60
5.42
2.7
4.4
64.56
111.77
mg/l
0.43
23
105
31
125
2.60
5.42
2.7
4.4
35.32
33.11
mg/l
0.18
23
106
198
1499
1.61
5.37
3.8
3.0
209.74
163.49
ug/l
0.98
185
1394
29
115
2.64
5.25
2.6
4.1
2.63
2.73
ratio
0.02
15
69
22
75
3.04
5.22
1.4
1.6
—
—
—
0
0
97
614
1.76
5.21
1.9
1.7
1155.04
1209.85
nmol/l
0.24
77
478
219
1723
1.57
4.89
17.1
15.3
1.22
1.29
inr
1.35
190
1462
49
253
2.06
4.88
2.2
1.7
—
—
—
0
0
27
108
2.60
4.81
1.2
1.3
—
—
—
0
0
70
413
1.84
4.73
2.4
1.8
2.16
1.56
%
3.18
62
364
45
228
2.09
4.71
4.4
3.8
1.37
1.81
mmol/l
0.29
36
165
198
1535
1.55
4.64
2.6
2.1
87.68
95.89
pmol/l
2.41
144
816
162
1216
1.54
4.31
4.0
3.6
43.73
118.65
e6/l
0.73
134
944
142
1040
1.55
4.19
3.8
3.5
0.49
0.53
e6/l
0.07
118
778
9
13
7.05
4.18
1.1
1.0
1586.44
1303.62
miu/ml
—
9
13
13
30
4.44
4.16
1.2
1.1
—
—
—
0
0
217
1745
1.51
4.12
10.5
7.6
1.20
1.21
mmol/l
0.23
180
1488
198
1575
1.49
3.89
9.7
6.8
1.20
1.21
mmol/l
0.06
189
1436
147
1102
1.52
3.84
2.4
2.2
310.52
321.00
u/l
0.03
142
1048
179
1400
1.49
3.80
2.9
2.4
73.52
77.06
nmol/l
0.92
170
1241
12
29
4.23
3.73
1.2
1.1
—
—
—
0
0
23
97
2.45
3.72
2.1
1.6
—
—
—
0
0
14
40
3.59
3.64
3.7
2.6
—
—
—
0
0
32
163
2.04
3.34
1.8
1.7
0.45
0.30
mg/l
0.66
23
79
61
383
1.69
3.33
5.8
4.3
1.24
1.67
mmol/l
0.42
52
316
15
55
2.79
3.19
1.9
1.7
—
—
—
0
0
247
2104
1.43
3.12
6.9
5.2
6.90
6.78
mmol/l
0.31
238
2004
64
415
1.64
3.09
3.3
3.5
7.40
9.44
umol/l
0.36
58
377
144
1122
1.43
2.96
3.0
2.6
51.40
60.40
u/l
1.29
136
1049
212
1771
1.40
2.92
4.6
3.9
0.00
0.00
estimate
-0.00
65
395
18
77
2.40
2.86
1.4
1.2
—
—
—
0
0
128
982
1.44
2.85
4.2
3.4
0.00
0.08
estimate
0.50
56
313
214
1796
1.39
2.84
4.6
3.9
0.00
0.00
estimate
-0.00
65
403
14
53
2.70
2.82
2.1
3.1
35.07
32.94
pg
1.39
14
53
214
1805
1.38
2.71
4.7
4.0
0.05
0.82
estimate
0.47
62
372
92
668
1.48
2.71
4.3
3.2
2.46
2.44
mmol/l
0.43
79
597
51
324
1.65
2.68
4.5
2.3
55.16
185.10
u/l
0.41
43
271
11
35
3.20
2.66
1.3
1.1
—
68.00
—
0
5
272
2391
1.40
2.66
5.8
3.8
14.80
14.91
pmol/l
0.29
256
2149
255
2220
1.38
2.63
5.7
4.6
2050.20
421.21
e6/l
—
5
39
10
30
3.39
2.62
1.6
3.5
784.70
1052.50
mg
—
10
30
20
95
2.16
2.53
2.0
2.2
132.43
129.66
g/l
0.20
14
73
97
721
1.45
2.53
1.9
1.8
427.27
19371287.58
pmol/l
0.50
85
604
70
487
1.53
2.52
1.5
1.6
—
—
—
0
0
133
1048
1.40
2.50
4.3
3.8
0.00
0.01
estimate
0.78
58
364
14
57
2.51
2.47
1.4
1.1
—
—
—
0
0
14
57
2.51
2.47
1.4
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
24
124
1.99
2.46
3.5
2.7
0.39
0.31
iu/ml
0.38
13
71
18
83
2.22
2.44
1.8
1.3
252.85
326.89
ug/g
1.10
13
50
20
97
2.12
2.41
5.2
3.1
1.30
2.52
index
—
10
56
146
1175
1.37
2.40
3.3
3.4
2752.28
1630.11
ng/l
0.54
138
1013
5
8
6.31
2.38
1.2
1.0
—
—
—
0
0
21
105
2.05
2.35
1.3
1.5
—
—
—
0
0
11
40
2.80
2.29
1.1
1.1
—
—
—
0
0
10
35
2.90
2.22
1.7
1.7
—
—
—
0
0
165
1371
1.34
2.17
4.5
3.8
0.02
0.01
estimate
0.09
59
328
7
19
3.73
2.16
12.6
13.5
725.86
843.68
nmol/l
—
7
19
15
70
2.19
2.00
3.3
2.0
—
—
—
0
0
144
1184
1.33
2.00
4.2
4.3
6.09
9.62
mg/mmol
1.05
93
783
251
2230
1.32
2.00
4.9
3.4
70.23
52.14
u/l
1.20
245
2099
148
1223
1.33
1.99
3.4
3.4
7.50
8.25
mmol/l
1.05
123
1034
6
16
3.79
1.94
1.0
1.3
—
—
—
0
0
6
16
3.79
1.94
1.0
1.3
—
—
—
0
0
18
92
2.00
1.93
1.2
1.2
—
—
—
0
0
18
92
2.00
1.93
1.2
1.2
—
—
—
0
0
8
28
2.89
1.87
1.1
1.0
—
—
—
0
0
20
109
1.88
1.80
1.2
1.3
—
—
—
0
0
82
628
1.38
1.79
2.7
2.0
—
—
—
0
0
6
18
3.37
1.75
1.0
1.4
—
—
—
0
0
6
18
3.37
1.75
1.0
1.4
—
—
—
0
0
6
18
3.37
1.75
2.7
4.1
1.33
1.06
%
—
6
18
13
61
2.17
1.73
1.3
1.2
—
—
—
0
0
13
61
2.17
1.73
1.5
1.2
—
63.89
—
0
9
7
24
2.95
1.73
1.7
1.8
—
—
—
0
0
5
13
3.88
1.72
2.4
1.0
—
—
—
0
0
38
254
1.55
1.67
3.4
3.3
128.37
130.68
g/l
0.28
38
246
16
83
1.96
1.67
1.3
1.5
—
—
—
0
0
8
31
2.61
1.66
1.8
1.7
—
—
—
0
0
6
19
3.19
1.66
1.0
1.3
—
—
—
0
0
6
19
3.19
1.66
6.3
2.4
99.50
109.84
%
—
6
19
167
1434
1.27
1.62
4.6
4.1
57.04
40.51
ng/l
0.43
133
1100
81
1022
0.74
1.62
3.0
3.3
0.51
0.80
ug/l
8.17
61
659
15
77
1.98
1.61
1.7
1.9
607.24
8032.10
u/l
—
9
27
7
26
2.72
1.58
1.7
1.7
—
—
—
0
0
11
50
2.23
1.58
1.7
1.8
—
—
—
0
0
5
15
3.36
1.52
1.2
1.0
344.20
149.47
iu/ml
—
5
15
6
21
2.88
1.51
1.2
1.4
—
—
—
0
0
18
102
1.80
1.47
3.3
1.8
—
—
—
0
0
22
133
1.69
1.45
3.3
2.0
—
—
—
0
0
19
110
1.76
1.45
3.4
1.8
—
—
—
0
0
12
59
2.06
1.45
6.2
3.0
14.54
10.04
pmol/l
0.38
12
59
66
506
1.36
1.45
1.4
1.3
13.35
15.88
u/ml
0.09
27
204
21
126
1.70
1.43
1.9
1.8
—
—
—
0
0
80
634
1.32
1.41
3.4
3.1
1.05
0.92
e6/l
0.16
49
351
14
74
1.92
1.40
1.2
1.3
—
—
—
0
0
9
41
2.22
1.37
1.0
1.7
—
—
—
0
0
16
90
1.81
1.35
1.6
1.4
230.80
274.36
miu/ml
—
5
42
12
61
2.00
1.34
1.2
1.5
—
151.40
—
0
15
0
40
0.00
1.33
0.0
1.2
—
7.73
—
0
33
8
34
2.38
1.30
1.3
1.2
—
—
—
0
0
5
18
2.80
1.29
2.4
2.9
3795.80
896.67
u/ml
—
5
18
18
107
1.71
1.28
1.4
1.4
—
—
—
0
0
9
44
2.07
1.27
1.6
1.5
—
—
—
0
0
69
544
1.32
1.27
1.4
1.3
24.37
35.49
iu/ml
0.54
24
176
6
25
2.42
1.25
1.0
1.2
—
—
—
0
0
9
45
2.02
1.24
1.6
1.5
—
—
—
0
0
9
45
2.02
1.24
1.6
1.5
—
—
—
0
0
9
45
2.02
1.24
1.6
1.5
—
—
—
0
0
5
19
2.65
1.22
1.0
1.4
—
—
—
0
0
5
19
2.65
1.22
1.0
1.4
—
—
—
0
0
60
467
1.33
1.21
9.6
7.4
1.31
0.84
mmol/l
0.31
48
381
8
155
0.51
1.16
3.5
1.8
—
—
—
0
0
342
3255
1.28
1.15
30.2
17.2
24.86
26.17
mg/l
0.34
316
2693
5
20
2.52
1.15
1.0
1.1
—
—
—
0
0
56
439
1.32
1.09
2.4
2.0
—
—
—
0
0
101
856
1.24
1.06
4.5
2.6
—
—
—
0
0
9
46
1.98
1.04
1.6
1.5
—
—
—
0
0
9
46
1.98
1.04
1.6
1.5
—
—
—
0
0
83
692
1.25
1.01
4.5
4.0
698.78
529.94
ng/l
0.18
72
568
91
767
1.24
1.00
2.3
1.7
1.87
1.52
mg/l
0.40
71
607
310
3252
0.82
1.00
6.9
5.8
2.49
2.62
mmol/l
1.86
289
3004
30
218
1.41
0.94
1.9
1.5
—
—
—
0
0
22
151
1.48
0.92
1.5
1.3
—
—
—
0
0
73
607
1.25
0.91
3.8
3.3
1.85
1.57
e6/l
0.21
41
330
32
237
1.38
0.91
1.8
1.6
—
—
—
0
0
8
44
1.83
0.86
4.6
2.2
—
—
—
0
0
15
96
1.58
0.85
1.5
1.4
24245.43
11897.95
e6/l
—
7
73
121
1363
0.84
0.85
3.7
4.5
16.60
21.75
%
3.33
56
677
8
46
1.75
0.83
4.7
4.8
322.75
325.19
umol/l
—
8
40
20
280
0.70
0.80
1.9
1.5
—
—
—
0
0
11
66
1.68
0.79
1.3
1.5
—
—
—
0
0
13
82
1.60
0.79
1.5
1.6
—
—
—
0
0
0
26
0.00
0.78
0.0
1.1
—
19.38
—
0
13
309
2950
1.18
0.78
6.4
4.8
1.82
1.95
mu/l
1.27
293
2685
174
1593
1.16
0.76
4.4
3.0
—
—
estimate
—
0
0
7
38
1.86
0.74
1.3
1.2
—
—
—
0
0
14
92
1.54
0.73
1.8
1.6
—
—
—
0
0
13
84
1.57
0.72
1.8
1.6
—
—
—
0
0
15
101
1.50
0.71
1.5
1.3
—
—
—
0
0
158
1721
0.87
0.70
4.9
5.6
2.93
2.82
ug/l
0.05
139
1532
7
43
1.64
0.67
1.3
1.1
—
—
—
0
0
8
128
0.62
0.65
3.3
1.7
—
—
—
0
0
296
3075
0.87
0.61
7.2
6.7
39.41
40.05
mmol/mol
0.58
281
2867
307
3176
0.87
0.56
6.2
5.0
1.35
1.39
mmol/l
1.19
285
2931
55
476
1.18
0.50
2.3
1.9
—
—
—
0
0
19
145
1.33
0.49
2.6
3.2
—
—
—
0
0
20
157
1.29
0.44
1.3
2.2
40.87
39.27
u/l
0.14
15
138
322
3131
1.12
0.44
29.6
16.6
80.44
79.22
ml/min/173m2
0.42
311
2922
5
31
1.62
0.43
1.4
1.2
88.40
103.94
pmol/l
—
5
31
10
70
1.44
0.42
2.1
1.7
—
—
—
0
0
5
34
1.48
0.40
1.0
1.2
258.00
191.96
pmol/l
—
5
34
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
311
3189
0.90
0.38
7.2
5.1
4.34
4.48
mmol/l
1.85
291
2962
180
1890
0.92
0.37
3.2
2.9
—
—
—
0
0
6
41
1.47
0.36
2.8
4.2
—
—
—
0
0
6
41
1.47
0.36
5.7
2.2
—
—
—
0
0
142
1337
1.09
0.36
2.4
2.0
1.39
1.36
mmol/l
0.15
118
1114
5
77
0.65
0.36
1.2
1.3
—
—
—
0
0
38
434
0.86
0.34
4.4
5.0
29.89
31.29
%
0.28
28
288
6
88
0.68
0.33
6.0
3.9
20.18
29.92
mg/l
—
6
66
8
107
0.74
0.29
1.0
1.1
0.78
0.91
g/l
—
8
107
9
76
1.19
0.24
1.9
1.2
33.10
47.19
u/l
—
9
64
5
42
1.19
0.21
1.6
1.2
—
—
—
0
0
30
268
1.13
0.21
1.9
1.5
—
—
—
0
0
30
268
1.13
0.21
4.4
3.3
59.91
65.81
ml/min/173m2
0.50
11
114
8
104
0.76
0.21
1.0
1.1
1.55
1.53
g/l
—
8
104
29
323
0.89
0.20
2.7
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
2.5
—
—
—
0
0
43
395
1.10
0.19
2.5
4.9
42.30
44.46
ug/l
0.02
36
331
7
62
1.13
0.17
1.7
1.5
—
—
—
0
0
7
63
1.11
0.17
1.4
1.2
79.43
14.51
e6/l
—
7
51
85
810
1.06
0.16
4.7
3.8
1.02
1.02
kg/l
0.37
68
542
309
3131
0.95
0.15
5.8
5.1
6.06
6.07
mmol/l
0.05
293
2853
27
287
0.94
0.08
2.7
1.9
—
—
—
0
0
7
64
1.10
0.08
1.4
1.3
10.57
178.67
e6/l
—
7
54
17
156
1.09
0.08
1.1
1.0
—
—
—
0
0
18
168
1.07
0.06
1.2
1.2
64.54
156.99
u/ml
—
5
61
18
172
1.05
0.02
1.4
1.3
—
33.16
—
0
16
38
381
1.00
0.00
13.8
6.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
75.50
—
0
6
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
34.00
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
32.11
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.6
—
13.26
—
0
8
5
56
0.89
-0.00
1.4
1.1
1.66
1.54
g/l
—
5
51
304
3040
1.00
-0.00
6.4
4.3
1.41
1.29
mmol/l
1.90
282
2785
Mortality – FinRegistry
↥Association
Association between endpoint L12_EXFOLIATIVE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_EXFOLIATIVE | 2.068 [1.66, 2.57] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.049 |
During the follow-up period (1.1.1998 — 31.12.2019), 324 out of 966 females with L12_EXFOLIATIVE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_EXFOLIATIVE | 2.357 [1.97, 2.82] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 723 out of 1728 males with L12_EXFOLIATIVE died.
Mortality risk
Mortality risk for people of age
years, who have L12_EXFOLIATIVE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.14% | 0.419% |
| 5 | 1.185% | 2.546% |
| 10 | 2.717% | 6.481% |
| 15 | 5.238% | 11.839% |
| 20 | 9.028% | 19.972% |
Relationships between endpoints
↥Index endpoint: L12_EXFOLIATIVE – Exfoliative dermatitis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data